Wright Medical Group N.V. Highlights Recent Innovations and Clinical Data at the American Orthopaedic Foot & Ankle Society (A...
September 12 2019 - 6:00AM
Wright Medical Group N.V. (NASDAQ: WMGI) announced it will
highlight new innovations at the American Orthopaedic Foot &
Ankle Society (AOFAS) 2019 Annual Meeting taking place at the Hyatt
Regency Chicago in Chicago, Illinois, from September 12-15,
2019. Wright will feature its full range of lower extremities
and biologic solutions at exhibit booth #133, including the
Cartiva® synthetic cartilage implant, PROstep™ minimally invasive
surgery system, Total Ankle continuum of care and AUGMENT®
Injectable bone graft.
Wright Medical also recently completed enrollment in its
UK-based post-market INFINITY™ Total Ankle Replacement follow-up
study. With 500 patients enrolled across 12 sites in the UK,
this marks one of the largest total ankle replacement studies ever
conducted. The multicenter, prospective study will evaluate
10-year implant survivorship and outcomes associated with the
INFINITY Total Ankle System. Study investigators include 20
non-inventor surgeons led by Mr. David Townshend, MBBS FRCS (Orth),
Consultant Orthopedic Surgeon, Northumbria NHS Healthcare Trust,
UK.
Robert Palmisano, president and chief executive officer,
commented, “We have continued to expand our best-in-class foot and
ankle product portfolio to meet the needs of orthopaedic surgeons
and patients and further enhance our leadership position in the
fast-growing lower extremities and biologics markets. At this
year’s AOFAS meeting, a number of presentations and posters will
highlight the growing body of compelling clinical evidence for our
market leading lower extremities product portfolio, including the
Cartiva synthetic cartilage implant, our total ankle replacement
product portfolio and AUGMENT bone graft.”
Palmisano continued, “Completing enrollment in our UK
post-market INFINITY study is an important milestone for total
ankle replacement and represents our ongoing commitment to surgeons
and their patients. The data collected by this study will
drive the continued evolution of treatment options that improve
quality of life for patients suffering from end-stage ankle
arthritis. We are especially proud that one poster
presentation demonstrated a significant reduction and cessation in
post-operative opioid consumption using Wright’s PROstep
minimally-invasive surgery products and was recognized as a
finalist for the prestigious Roger A. Mann Award, which is given in
recognition of the outstanding clinical paper presented at the
AOFAS Annual Meeting.”
Wright will feature its full range of lower extremities and
biologic solutions at exhibit booth #133, including the following
products:
- CARTIVA® Synthetic Cartilage Implant (SCI) –
As the first new articulating surface material to receive U.S.
Premarket Approval (PMA) by the FDA in 18 years, the CARTIVA SCI is
indicated for treating arthritis at the base of the great toe and
the only product of its kind backed by Level 1 clinical
evidence. Unlike fusion, Cartiva reduces joint pain without
sacrificing the foot’s natural movement and retains mobility and
range of motion. More information on the CARTIVA SCI can be
found at www.cartiva.net.
- PROstep™ Minimally Invasive Surgery (MIS)
System – Specifically designed for foot and ankle surgery,
the PROstep system provides a minimally invasive, procedurally
integrated solution that features specifically designed implants
and instrumentation for percutaneous surgery of the foot. The
PROstep System can be used to treat a variety of forefoot and
hindfoot pathologies, including one of the most common, Hallux
Valgus, commonly known as bunions, a painful foot deformity that is
prevalent in approximately 23% in adults aged 18-65 years and 35.7%
in elderly people aged over 65 yearsi. Compared to a
traditional open surgery, the PROstep System has been shown to get
patients back on their feet faster, with less pain and an improved
cosmetic result. More information on PROstep can be found at
www.ProstepMIS.com.
- AUGMENT® Injectable Bone Graft – AUGMENT
Injectable is the first clinically proven injectable protein
therapeutic to come to the U.S. orthopaedic market offering an
alternative to autograft in ankle and/or hindfoot fusion
procedures, which translates into an estimated market opportunity
of approximately $300 million in the U.S. The launch of
AUGMENT Injectable provides foot and ankle surgeons in the U.S.
with a safe and effective alternative to autograft that includes
significantly improved handling characteristics to enable easier
and more precise delivery to the fusion site, while eliminating the
need for autograft and the associated morbidities of autograft
harvest. More information on AUGMENT can be found at
www.augmentbonegraft.com.
- Total Ankle Continuum of Care – Comprised of
Wright’s INBONE™ and INFINITY™ Total Ankle Systems, the INVISION™
Total Ankle Revision System and PROPHECY™ Preoperative Navigation
System, this comprehensive product portfolio is the surgeons #1
choice for primary and revision ankle arthroplasty. The
INFINITY total ankle system combines a low-profile tibial implant
design with a resurfacing talar component designed for full
fluoroscopic visualization to ensure proper implant seating.
The INVISION™ Total Ankle Revision System is the first and only
system developed specifically for total ankle revision arthroplasty
and is now available with preoperative planning. The PROPHECY
Preoperative Navigation System is the first and only preoperative
navigation for total arthroplasty, combining computer imaging and
the patient’s own CT scan data to create patient-specific alignment
guides for use during the surgical operation. More
information on Wright’s total ankle products can be found at
www.myankle.com/.
Internet Posting of Information
Wright routinely posts information that may be important to
investors in the “Investor Relations” section of its website at
www.wright.com. The company encourages investors and
potential investors to consult the Wright website regularly for
important information about Wright.
About Wright Medical Group N.V.
Wright Medical Group N.V. is a global medical device company
focused on extremities and biologics products. The company is
committed to delivering innovative, value-added solutions improving
quality of life for patients worldwide and is a recognized leader
of surgical solutions for the upper extremity (shoulder, elbow,
wrist and hand), lower extremity (foot and ankle) and biologics
markets, three of the fastest growing segments in
orthopedics. For more information about Wright, visit
www.wright.com.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements under the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this release include, but are not
limited to, statements about the performance and market acceptance
of the company’s products. Forward-looking statements by their
nature address matters that are, to different degrees, uncertain.
Each forward-looking statement contained in this release is subject
to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such
statement. Applicable risks and uncertainties include, among
others, physician acceptance, endorsement, and use of company
products; the effect of regulatory actions, changes in and adoption
of reimbursement rates; product liability claims; product recalls;
the effects of industry, economic or political conditions outside
of the company’s control; competitor activities; and the risks
identified under the heading “Risk Factors” in Wright’s Annual
Report on Form 10-K for the year ended December 30, 2018 filed by
Wright with the SEC on February 27, 2019 and subsequent SEC
filings by Wright, including without limitation its Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2019 and
June 30, 2019. Investors should not place considerable
reliance on the forward-looking statements contained in this
release. Investors are encouraged to read Wright’s filings with the
SEC, available at www.sec.gov, for a discussion of these and other
risks and uncertainties. The forward-looking statements in this
release speak only as of the date of this release, and Wright
undertakes no obligation to update or revise any of these
statements. Wright’s business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
i
https://jfootankleres.biomedcentral.com/articles/10.1186/1757-1146-3-21
Investors & Media:
Julie D. DeweySr. Vice President, Chief Communications
OfficerWright Medical Group N.V.(901)
290-5817julie.dewey@wright.com
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Apr 2023 to Apr 2024